A 24-week, parallel-group, open-label, randomized trial comparing Telbivudine with Entecavir treatment in HBeAg-positive chronic hepatitis B patients.

Trial Profile

A 24-week, parallel-group, open-label, randomized trial comparing Telbivudine with Entecavir treatment in HBeAg-positive chronic hepatitis B patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2012

At a glance

  • Drugs Entecavir (Primary) ; Telbivudine (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 May 2012 Planned end date changed from 2 Oct 2008 to 30 Oct 2009 as reported by Chinese Clinical Trial Register.
    • 20 Dec 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top